GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

StimCell Enegetics STME · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.22

0.00%

Close of 6 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

—

FY2017FY2026

Net income

−$895,375

FY2017FY2026

Free cash flow

−$312,081

FY2017FY2026

Shareholders' equity

−$1.8m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue———$2,762$6,065$6,065$95,824$95,824—$6,220
Gross profit———$483$4,033$4,033$85,588$85,588−$580$2,169
Research and development$209,176$64,009$22,539$89,220$150,709$229,581$393,216$261,907$418,319$297,043
Operating income−$820,526−$504,949−$313,430−$447,658−$671,693−$671,693−$1.0m−$1.0m−$1.5m−$1.6m
Net income−$895,375−$566,293−$142,486−$495,042−$697,379−$910,836−$1.1m−$922,702−$1.5m−$1.2m
Diluted earnings per share-0.04-0.03-0.01-0.01-0.01-0.01-0.02-0.02-0.03-0.03

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$81,454$21,222$46,122$103,270$41,344$52,242$159,179$190,541$45,259$293,728
Cash and short-term investments$3,057$14,581$43,415$98,295—$20,753$45,090$57,172$8,200$67,494
Total liabilities$1.9m$1.3m$872,577$2.5m$2.1m$1.6m$1.7m$2.0m$1.1m$1.5m
Debt$691,064$458,972$313,490$1.0m—$616,781$502,437$511,754$117,459$541,298
Shareholders' equity−$1.8m−$1.2m−$826,455−$2.4m−$2.0m−$1.6m−$1.5m−$1.8m−$1.1m−$1.2m
Shares outstanding21m21m20m63m63m63m59m55m44m42m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$312,081−$141,600−$145,898−$272,209−$450,591−$560,432−$925,844−$307,542−$449,427−$754,059
Capital spending—————−$1,574−$2,463−$1,915—−$110,234
Free cash flow−$312,081−$141,600−$145,898−$272,209−$450,591−$562,006−$928,307−$309,457−$449,427−$864,293

Latest quarters

By quarter end

Aug 2026May 2026Feb 2026Nov 2025Aug 2025May 2025Feb 2025Nov 2024
Operating income—−$192,851−$102,054−$271,498−$254,123−$261,646−$89,534−$79,924
Net income−$169,518−$229,459−$90,566−$309,748−$265,602−$219,329−$140,537−$139,508
Diluted earnings per share-0.01-0.01-0.00-0.01-0.01-0.01-0.01-0.01
Total assets$60,946$81,454$34,521$52,345$16,387$21,222$17,110$38,346
Cash and short-term investments$6,883$3,057$10,257$46,159$6,437—$6,678$33,821
Debt—$691,064$779,992$698,193$458,972—$378,174$355,777
Shareholders' equity−$2.0m−$1.8m−$1.7m−$1.5m−$1.4m−$1.2m−$1.1m−$982,705

Growth per year

Compound annual rate

3 years5 years10 years
Operating income22.4%4.1%-3.9%
Net income21.8%-0.3%-8.3%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023
Price to earnings-6.2-14.6-2.3-0.0
Price to sales———1.6

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return6328%5730%293713%-59%-39%-14%365%-12%-5%92%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 15-to-1 reverse split · 5 Nov 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.